Vipidia (alogliptin)

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for Vipidia, 6.25 mg, 12.5 mg and 25 mg, film-coated tablet intended for the treatment of type 2 diabetes mellitus (European Medicines Agency)